Abstract
Lactic acid bacteria (LAB) are gaining importance due to their “generally recognized as safe” status, long-term use in food and beneficial, probiotic properties. They can acquire new, desirable traits by the incorporation of genes that allow the expression of heterologous proteins, and several patents and patent applications describe the use of recombinant LAB. We first focus on the available expression systems, their improvement towards “food-grade” status, and modes of regulating the expression. LAB have been used as vehicles for the delivery of proteins to the mucosal surfaces. Delivered proteins may interact with the immune system and have been shown to be effective, either as vaccines or as toleranceinducing, anti-allergy agents in mice. Proteins with biological functions that could be used in therapy have also been delivered. Delivery of interleukin 10 (IL-10) in Crohns disease, which was tested in a human phase I clinical trial and has proceeded to phase IIa, is the first example of use of recombinant LAB in humans. Another field of recombinant LAB application is metabolic engineering. Existing metabolic pathways have been modified to improve the properties of LAB as food fermentation starters, and heterologous metabolic enzymes have been introduced to LAB for the production of industrially relevant chemicals.
Keywords: Lactic acid bacteria, Lactococcus, Lactobacillus, recombinant protein, vaccine, allergen, antigen, expression, delivery, metabolic engineering
Recent Patents on Biotechnology
Title: Novel Applications of Recombinant Lactic Acid Bacteria in Therapy and in Metabolic Engineering
Volume: 3 Issue: 2
Author(s): Ales Berlec and Borut Strukelj
Affiliation:
Keywords: Lactic acid bacteria, Lactococcus, Lactobacillus, recombinant protein, vaccine, allergen, antigen, expression, delivery, metabolic engineering
Abstract: Lactic acid bacteria (LAB) are gaining importance due to their “generally recognized as safe” status, long-term use in food and beneficial, probiotic properties. They can acquire new, desirable traits by the incorporation of genes that allow the expression of heterologous proteins, and several patents and patent applications describe the use of recombinant LAB. We first focus on the available expression systems, their improvement towards “food-grade” status, and modes of regulating the expression. LAB have been used as vehicles for the delivery of proteins to the mucosal surfaces. Delivered proteins may interact with the immune system and have been shown to be effective, either as vaccines or as toleranceinducing, anti-allergy agents in mice. Proteins with biological functions that could be used in therapy have also been delivered. Delivery of interleukin 10 (IL-10) in Crohns disease, which was tested in a human phase I clinical trial and has proceeded to phase IIa, is the first example of use of recombinant LAB in humans. Another field of recombinant LAB application is metabolic engineering. Existing metabolic pathways have been modified to improve the properties of LAB as food fermentation starters, and heterologous metabolic enzymes have been introduced to LAB for the production of industrially relevant chemicals.
Export Options
About this article
Cite this article as:
Berlec Ales and Strukelj Borut, Novel Applications of Recombinant Lactic Acid Bacteria in Therapy and in Metabolic Engineering, Recent Patents on Biotechnology 2009; 3 (2) . https://dx.doi.org/10.2174/187220809788700175
DOI https://dx.doi.org/10.2174/187220809788700175 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Connections Among Autophagy, Inflammasome and Mitochondria
Current Drug Targets Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Patent Selections
Recent Patents on Biotechnology Menstrual and Reproductive Outcomes Following Uterine Artery Fibroid Embolisation: A Literature Review
Current Women`s Health Reviews Overview of Angiogenesis and the use of Bevacizumab in Patients with Malignant Gliomas
Current Signal Transduction Therapy Feasibility of Assam Bora Rice Starch as a Compression Coat of 5-Fluorouracil Core Tablet for Colorectal Cancer
Current Drug Delivery Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Nutrition in Allogeneic Stem Cell Transplantion - Clinical Guidelines and Immunobiological Aspects
Current Pharmaceutical Biotechnology <i>Ralstonia Mannitolilytica</i>, an Unusual Pathogen in the Neonatal Intensive Care Unit: A Case of Neonatal Sepsis and Literature Review
Infectious Disorders - Drug Targets NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Rabbit as an Animal Model for Pharmacokinetics Studies of Enteric Capsule Contains Recombinant Human Keratinocyte Growth Factor Loaded Chitosan Nanoparticles
Current Clinical Pharmacology Therapeutic Manipulation of the Immune System: Enhancement of Innate and Adaptive Mucosal Immunity
Current Pharmaceutical Design Recent Advances in the Development of Immunoadhesins for Immune Therapy and as Anti-Infective Agents
Recent Patents on Anti-Infective Drug Discovery MicroRNAs: Regulators of TLR2-Mediated Probiotic Immune Responses
MicroRNA Derivatives of IL-16 to Modulate Airway Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of Regulatory T Cells in Allergy: Implications for Therapeutic Strategy
Inflammation & Allergy - Drug Targets (Discontinued) Aspirin: A Potential Therapeutic Approach in Pancreatic Cancer
Current Medicinal Chemistry Inflammatory Bowel Disease and Celiac Disease: Overlaps in the Pathology and Genetics, and their Potential Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Pathogenesis and Biomarkers in Spondyloarthritis: Clues from Microarray Analyses
Current Rheumatology Reviews